Abstract：Objective To investigate the efficacy of prostate imaging reporting and data system v2(PI-RADS v2)at 3 points in the diagnosis of prostate cancer by using prostate specific antigen mass ratio (PSAMR).Methods The clinical data of 81 patients with PI-RADS v2 score of 3 who were admitted to the affiliated hospital of Panzhihua university from January 2016 to August 2020 were retrospectively analyzed. All patients underwent multiparameter MRI examination and needle biopsy guided by B-ultrasound. Based on pathological diagnosis, patients were divided into prostate cancer group (19 cases) and nonprostate cancer group (62 cases). The differences of age, prostate volume, PSA, PSAD, PSAM and PSAMR between two groups were compared. Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of each index in prostate cancer with PI-RADS v2 score of 3.Results Single factor analysis of the basic data of the two groups showed that there were statistically significant differences in age, PSA, PSAD, PSAM, PSAMR and prostate volume between the two groups (all P<0.05). Multivariate logistic regression analysis showed that there were statistically significant differences in PSAD, PSAM and PSAMR between the two groups (all P<0.05). The areas under ROC curve of PSA, PSAD, PSAM and PSAMR in diagnosing PI-RADS v2 with 3 points of prostate cancer were 0.703, 0.769, 0.790 and 0.823, respectively. The specificity of PSA, PSAD, PSAM and PSAMR in the diagnosis of PI-RADS v2 was 0.889, 0.722, 0.889 and 0.944, respectively. The sensitivity of PSA, PSAD, PSAM and PSAMR in diagnosing PIRADS v2 was 0.468, 0.742, 0.694 and 0.645, respectively. The area and specificity under ROC curve of PSMAR diagnosis were higher than the other three indexes.Conclusions PSAMR has high diagnostic efficiency in the diagnosis of prostate cancer patients with PI-RADS v2 score of 3, and the patients with prostate disease whose PI-RADS v2 score is 3 in clinical work can get more accurate diagnosis with PSAMR.
